IL-17、IL-23在接受利妥昔单抗治疗的B细胞非霍奇金淋巴瘤患者中的表达
Expression of IL-17 and IL-23 in Patients with B-cell non-HodgkinLymphoma Treated by RCHOP
-
摘要: 目的 检测B细胞非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)患者治疗前后IL-17、IL-23表达水平的变化,探讨IL-17、IL-23在NHL发生发展过程中的作用.方法 应用逆转录-聚合酶链式反应(reverse transcription-polymerase chain reaction,RT-PCR)法检测25例接受标准剂量R-CHOP方治疗6~8个疗程的B细胞NHL患者和20例健康对照组.结果 NHL患者初诊时和缓解时外周血中IL-17m RNA的表达水平均低于健康对照组(P<0.05).NHL患者缓解时与初诊时相比,IL-17m RNA的表达水平有所升高(P=0.001,P<0.05).NHL患者初诊时和缓解时外周血中IL-23m RNA的表达水平均低于健康对照组(P<0.05).缓解时与初诊时相比,IL-23m RNA的表达水平升高,(P=0.004,P<0.05).结论 B细胞非霍奇金淋巴瘤患者接受利妥昔单抗治疗后IL-17、IL-23水平升高.IL-17、IL-23m RNA的表达与预后相关.Abstract: Objectives To study the role of IL-17 and IL-23 in non-Hodgkin lymphoma(NHL) by detecting the expression levels of IL-17 and IL-23 in peripheral blood of B-cell non-Hodgkin lymphoma patients treated by RCHOP.Methods T wenty-five patients with B-cell NHL who achieved remission after 6 to 8 cycles of R-CHOP as a NHL group,20 healthy volunteers were recruited as a normal control group.RT-PCR was used to detect the expression levels of IL-17 m RNA and IL-23 m RNA in NHL patients and health volunteers.Results The expression level of IL-17 m RNA and IL-23 m RNAin the patients with NHL before therapy and the patients with NHL who achieved remission was lower than that in the normal control group(P<0.05).The expression level of IL-17 m RNA and IL-23 m RNA in the patients with NHL who achieved remission was higher than that in the patients with NHL before therapy(P=0.001,P<0.05).Conclusion IL-17 and IL-23 m RNA expressions are higher after treated with R-CHOP.The expression levels of IL-17 m RNA and IL-23 m RNA in NHL patients are related with prognosis and efficacy.
-
Key words:
- Non-Hodgkin lymphoma /
- Interleukin-17 /
- Interleukin-23 /
- Rituximab /
- Prognosis
-
[1] [1]SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics[J].CA Cancer J Clin,2015,65(1):5-29. [2] [2]STASICR,DELPOETAG,STIPAE,et al.Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura[J].Blood,2007,110(8):2924-2930. [3] [3]STASI R,COOPERN,DELPOETAG,et al.Analysis of regulatory T-cell changes in patients with idiopathic throm bocytopenic purpura receiving B cell-depleting therapy with rituximab[J].Blood,2008,112(4):1147-1150. [4] [4]SHAHRARAS,HUANGQ,MANDELINAM,et al.TH-17cells in rheumatoid arthritis[J].Arthritis Res Ther,2008,10(4):R93. [5] [5]RACKEMK.Immunopathogenesis of multiple sclerosis[J].Ann Indian Acad Neurol,2009,12(4):215-220. [6] [6]ZHOU L,LITTMANDR.Transcriptional regulatory net works in Th17 cell differentiation[J].Curr Opin Im munol,2009,21(2):146-152. [7] [7]STARK M A,HUO Y,BURCIN T L,et al.Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23and IL-17[J].Immunity,2005,22(3):285-294. [8] [8]TZANKOVA,MEIERC,HIRSCHMANNP,et al.Correla tion of high numbers of intratumoral FOXP3+regulatory T cells with improved survival in germinal center like diffuse large B-cell lymphoma,follicular lymphoma and classical Hodgkin's lymphoma[J].Haematologica,2008,93(2):193-200. [9] [9]GHILARDIN,OUYANGW.Targeting the development and effector functions of TH17 cells[J].Semin Immunol,2007,19(6):383-393. [10] [10]SAKAGUCHIS.Regulatory T cells:key controllers of immuno logicself-tolerance[J].Cell,2000,101(5):455-458. [11] [11]PARK H,LI Z,YANG X O,et al.A distinct lineage of CD4 T cells regulates tissue inflammation by producing inter leukin 17[J].Nat Immunol,2005,6(11):1133-1141. [12] [12]OPPMANNB,LESLEYR,BLOMB,et al.Novel p19 pro tein engages IL-12p40 to form a cytokine from a cytokine,IL-23,with biological activities similar as well as distinct from IL-12[J].Immunity,2000,13(5):715-725. [13] [13]LU T,YUS,LIUY,et al.Aberrant Circulating Th17 Cells in Patients with B-Cell Non-Hodgkin’s Lymphoma[J].PLo S One,2016,11(1):e0148044. [14] [14]CARRERAS J,LOPEZ-GUILLERMO A,FOXBC,et al.High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicu lar lymphoma[J].Blood,2006,108(9):2957-2964. [15] [15]VAN D E VEERDONKFL,LAUWERYSB,MARIJNIS SENRJ,et al.The anti-CD20 antibody rituximab reduces the Th17 cell response[J].Arthritis Rheum,2011,63(6):1507-1516. [16] [16]The International Non-Hodgkin’s Lymphoma Prognostic Factors Project.A predictive model for aggressive non-Hodgkin’s lymphoma[J].N Engl J Med,1993,329(14):987-994. [17] [17]KIKLY K,LIU L,NA S,et al.The IL-23/Th(17)axis:therapeutic targets for autoimmune inflammation[J].Curr Opin Immunol,2006,18(6):670-675. [18] [18]LANGOWSKI J L,ZHANG X,WU L,et al.IL-23promotes tumour incidence and growth[J].Nature,2006,442(7101):461-465. [19] [19]STANILOV N,MITEVA L,MINTCHEV N,et al.High expression of Foxp3,IL-23p19 and survivin m RNA in colorectal carcinoma[J].Int J Colorectal Dis,2009,24(2):151-157.
点击查看大图
计量
- 文章访问数: 1854
- HTML全文浏览量: 726
- PDF下载量: 60
- 被引次数: 0